Fabrizio Citarella retweetledi
🫁 Can Local Ablative Therapy Add More Power To First-Line EGFR TKI Treatment?
A new systematic review and meta-analysis in the Journal of Thoracic Oncology evaluated the integration of local ablative therapy (LAT) with EGFR TKIs in advanced EGFR-mutated NSCLC.
The signal was clinically meaningful:
🔹 31 studies included
🔹 3,355 patients analyzed
🔹 PFS improved with LAT + EGFR TKI: HR 0.45
🔹 OS also favored LAT + EGFR TKI: HR 0.52
🔹 Benefit was seen with both upfront and consolidative LAT strategies
🔹 Pneumonitis was more frequent, but grade ≥3 toxicities were uncommon
As first-line EGFR+ NSCLC treatment becomes more complex, LAT may offer a different kind of intensification, focused, multidisciplinary, and potentially less systemically toxic.
The next question is not only whether LAT works, but which patients benefit most, when it should be delivered, and how it fits into the modern osimertinib era.
oncodaily.com/oncolibrary/lu…
@Brunet3Leon @GiuliaLaCavaMD @valentsant @pecci_federica1 @JuliaRotow @AminNassarMD @adib_elio @thenasheffect @M_Tagliamento @RobertoFerrara_ @FCitarellaMD @BRicciutiMD @finn_corinne @HendriksLizza @APassaroMD @dplanchard @PassigliaFra @ACortelliniMD
#LungCancer #NSCLC #EGFR #EGFRMutatedNSCLC #ThoracicOncology #RadiationOncology #SBRT #PrecisionOncology #OncoDaily
English
